The 12 Hallmarks of Aging in Dogs, Explained
Read full insightNicotinamide Riboside for Dogs
By La Petite Labs Editorial 16 min read
References
Numbered references identify the sources used for specific claims. Read the study design, species and evidence boundaries alongside each finding.
-
Ratajczak J, Joffraud M, Trammell SA, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Study design/context: Mechanistic studySpecies/context: mouse, mammalian cellsEvidence boundary: Experimental pathway work; not canine or feline absorption, dosing, or clinical efficacy.↩ 1 · ↩ 2 · ↩ 3 · ↩ 4
-
Marinescu AG, Chen J, Holmes HE, et al. Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm. Study design/context: 90-day oral toxicology study with recovery armSpecies/context: ratEvidence boundary: Sprague-Dawley rats, not dogs or cats. Rat toxicology cannot establish long-term pet safety or a pet serving.↩
-
Cardoso D, Barthélémy I, Blot S, et al. Replenishing NAD+ content reduces aspects of striated muscle disease in a dog model of Duchenne muscular dystrophy. Study design/context: Muscular dystrophy disease-model experimentSpecies/context: dogEvidence boundary: Dogs with inherited muscular dystrophy received NAM, not NR. Not healthy senior-dog or feline evidence.↩
-
Simon KE, Russell K, Mondino A, et al. A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination. Study design/context: Randomized controlled clinical trialSpecies/context: dogEvidence boundary: Combination-specific owner-assessed cognition result; does not isolate NR or establish efficacy of another formula.↩
-
Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Study design/context: Pharmacokinetic studySpecies/context: human, mouseEvidence boundary: Human and mouse NAD-related biomarkers; not clinical benefit or a dose for pets.↩ 1 · ↩ 2
-
Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Study design/context: Randomized placebo-controlled crossover trialSpecies/context: humanEvidence boundary: Older men; muscle NAD-related metabolites changed without improved mitochondrial bioenergetics. Not pet outcome evidence.↩
-
EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. Study design/context: Human novel-food safety assessment including canine dossier studiesSpecies/context: dogEvidence boundary: Short beagle metabolism and toxicity studies summarized in a human novel-food assessment; not a canine efficacy trial.↩ 1 · ↩ 2 · ↩ 3
-
Therapeutic Goods Administration. Nicotinamide riboside chloride. Study design/context: Ingredient composition specificationEvidence boundary: Not a finished product certificate or canine efficacy assessment.↩ 1 · ↩ 2 · ↩ 3
-
Liu L, Su X, Quinn WJ, et al. Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. Study design/context: Isotope tracing in cells and miceSpecies/context: mouse, cell linesEvidence boundary: Isotope tracing in cells and mice; does not quantify oral NR delivery to canine tissues.↩ 1 · ↩ 2
-
McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Study design/context: Randomized clinical trial in people with PADSpecies/context: humanEvidence boundary: Primary walking result used prespecified one-sided p<0.10; larger confirmation needed, not dog outcome evidence.↩
-
ThorneVet. Longevity Complex — manufacturer document, February 2024. Study design/context: Legacy manufacturer product documentSpecies/context: dog, catEvidence boundary: Manufacturer’s February 2024 ingredient declaration; current formulas may differ. Not a comparative efficacy study.↩
-
American Animal Hospital Association. Evaluating the Healthy Senior Pet. Study design/context: Senior-pet clinical assessment guidanceSpecies/context: dog, catEvidence boundary: Not an NR-specific interaction study or dosing recommendation.↩
-
Reactome. Complex I oxidises NADH to NAD+, reduces CoQ to CoQH2. Study design/context: Curated human respiratory-chain reactionSpecies/context: human biochemical pathwayEvidence boundary: Curated biochemical reaction, not a supplementation or finished-formula trial.↩
-
Reactome. GSR catalyzes glutathione (oxidized) + NADPH + H+ => 2 glutathione (reduced) + NADP+. Study design/context: Curated biochemical reactionSpecies/context: human biochemical pathwayEvidence boundary: Biochemical background on glutathione recycling; not evidence of an effect from an oral pet supplement.↩
Keep exploring
What would you like to understand next?
Search practical guides about healthy aging, cellular energy, ingredients, and daily support for dogs.

